| Technology |
HTA Report |
| Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) |
Nº 541 - June/2020 - Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma |
| Sirolimus |
Nº 539 - June/2020 - Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis |
| Tofacitinib Citrate (Xeljanz®) |
Nº 538 - June/2020 - Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs |
| Ruxolitinib (Jakavi®) |
Nº 531 - June/2020 - Ruxolitinib for the treatment of patients with primary myelofibrosis, postpolycythaemia vera myelofibrosis or postessential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease |
| Rifapentine plus isoniazid (3HP regimen) |
Nº 526 - June/2020 - Rifapentine plus isoniazid for treatment of Latent Mycobacterium Tuberculosis Infection (LTBI) |
| Rifampicin 300 mg capsule, and 20 mg/mL oral suspension |
Nº 525 - June/2020 - Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease |
| Empagliflozin and Dapagliflozin |
Nº 524 - March/2020 - Empagliflozin and Dapagliflozin for the treatment of Type 2 Diabetes Mellitus |
| Orlistat |
Nº 523 - March/2020 - Orlistat for weight loss in overweight or obese patients |
| Sibutramine |
Nº 522 - March/2020 - Sibutramine for the treatment of obese patients |
| Riociguat |
Nº 519 - March/2020 - Riociguat for inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension |
| Treatment of Pseudomyxoma Peritonei |
Nº 518 - April/2020 - Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) |
| Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) |
Nº 517 - April/2020 - Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma |
| Newborn Screening |
Nº 516 - March/2020 - Newborn Screening for Congenital Toxoplasmosis |
| Dolutegravir |
Nº 515 - March/2020 - Dolutegravir for the treatment of pregnant women living with HIV |
| Baricitinib (Olumiant®) |
Nº 510 - March/2020 - Baricitinib (Olumiant®) for patients with moderate to severe Active Rheumatoid Arthritis |
| Mirabegron |
Nº 509 - March/2020 - Mirabegron for the treatment of storage dysfunction in patients with Neurogenic Bladder |
| Oxybutynin, Tolterodine, Solifenacin and Darifenacin |
Nº 508 - March/2020 - Antimuscarinics (Oxybutynin, Tolterodine, Solifenacin and Darifenacin) for the treatment of Storage Dysfunction in patients with Neurogenic Bladder |
| Photodynamic Therapy |
Nº 507 - March/2020 - Photodynamic Therapy for non-melanoma skin câncer |
| Personal Frequency Modulation System |
Nº 506 - February - Personal frequency modulation system for hearing-impaired students at any age and at any academic level |
| Testing for prothrombin gene mutation (G202110A), protein C functional assay, protein S functional assay, anti-beta2-glycoprotein I - IgG, lupus anticoagulant |
Nº 503 - January/2020 - Diagnostic tests for thrombophilia in pregnancy |